Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Sandoz Biosimilars Earnings Up 21% in Q1/24 Underpinned By Ranibizumab & Adalimumab Launches

May 7, 2024

On 7 May 2024, Sandoz announced Q1 2024 net sales of USD1.9 billion, with its biosimilars growing 21% to USD 623 million.  The biosimilar growth is said to be driven by Sandoz’s 2023 US/EU launch of Hyrimoz®, biosimilar to AbbVie’s Humira® (adalimumab), and the acquisition of Cimerli®, biosimilar to Genentech’s Lucentis® (ranibizumab), announced in January 2024.  During the reported quarter, Sandoz also launched in Germany the Polpharma-developed Tyruko® (Biogen’s Tysabri®, natalizumab) and obtained US approval for Jubbonti® and Wyost® (Amgen’s Prolia®/Xgeva®, denosumab).